Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | Omipalisib | 1 | 72 | 0.0032 | 4586.5 | 5372.5 | 1554.9 | -2.49 | 0.831 | 0.854 | 1.789 | BT549 GSK458 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.0032 | 2831.8 | 4278.0 | 1295.5 | -2.49 | 0.574 | 0.662 | 1.723 | HCC38 Rapamycin 0 1 72 |
| BT-20 | Dactolisib | 2 | 72 | 0.0032 | 2500.5 | 3372.5 | 1018.6 | -2.49 | 0.682 | 0.741 | 1.727 | BT20 BEZ235 0 2 |
| BT-549 | Dactolisib | 3 | 72 | 0.0032 | 2896.0 | 4098.5 | 1175.8 | -2.49 | 0.649 | 0.707 | 1.801 | BT549 BEZ235 0 3 72 |
| BT-20 | PIK-93 | 3 | 72 | 0.0032 | 3404.3 | 3394.0 | 586.9 | -2.49 | 1.000 | 1.000 | 2.532 | BT20 PIK93 0 3 |
| HCC38 | Dactolisib | 2 | 72 | 0.0032 | 2294.8 | 3001.5 | 690.5 | -2.49 | 0.762 | 0.765 | 2.120 | HCC38 BEZ235 0 2 72 |
| BT-20 | Alpelisib | 3 | 72 | 0.0032 | 3274.5 | 3415.3 | 586.9 | -2.49 | 0.967 | 0.959 | 2.541 | BT20 BYL719 0 3 |
| HCC38 | Buparlisib | 2 | 72 | 0.0032 | 3145.3 | 3048.5 | 690.5 | -2.49 | 1.030 | 1.030 | 2.142 | HCC38 BKM120 0 2 72 |
| BT-549 | AS605240 | 1 | 72 | 0.0032 | 5357.5 | 5429.5 | 1554.9 | -2.49 | 0.985 | 0.987 | 1.804 | BT549 AS605240 0 1 72 |
| HCC70 | TGX221 | 1 | 72 | 0.0032 | 3182.3 | 3333.8 | 1279.8 | -2.49 | 0.934 | 0.955 | 1.381 | HCC70 TGX221 0 1 72 |
| HCC70 | Torin1 | 1 | 72 | 0.0032 | 2995.0 | 3250.8 | 1279.8 | -2.49 | 0.882 | 0.921 | 1.345 | HCC70 Torin1 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.0032 | 2749.5 | 3294.3 | 1279.8 | -2.49 | 0.752 | 0.835 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | PIK-93 | 1 | 72 | 0.0032 | 3227.0 | 3477.0 | 1279.8 | -2.49 | 0.899 | 0.928 | 1.442 | HCC70 PIK93 0 1 72 |
| HCC38 | PIK-93 | 1 | 72 | 0.0032 | 4262.8 | 4331.0 | 1295.5 | -2.49 | 0.982 | 0.984 | 1.741 | HCC38 PIK93 0 1 72 |
| BT-549 | AZD-6482 | 3 | 72 | 0.0032 | 3898.5 | 3938.5 | 1175.8 | -2.49 | 0.988 | 0.990 | 1.744 | BT549 AZD6482 0 3 72 |
| BT-20 | BX-912 | 3 | 72 | 0.0032 | 3155.3 | 3280.0 | 586.9 | -2.49 | 0.969 | 0.962 | 2.483 | BT20 BX912 0 3 |
| HCC38 | PI103 | 1 | 72 | 0.0032 | 4378.8 | 4454.3 | 1295.5 | -2.49 | 0.981 | 0.983 | 1.782 | HCC38 PI103 0 1 72 |
| BT-20 | MK2206 | 1 | 72 | 0.0032 | 5903.0 | 6138.5 | 1443.3 | -2.49 | 0.963 | 0.962 | 2.089 | BT20 MK2206 0 1 |
| BT-549 | AZD8055 | 2 | 72 | 0.0032 | 4117.5 | 4500.0 | 1249.6 | -2.49 | 0.906 | 0.915 | 1.848 | BT549 AZD8055 0 2 72 |
| HCC70 | PI103 | 1 | 72 | 0.0032 | 3251.5 | 3161.3 | 1279.8 | -2.49 | 1.040 | 1.030 | 1.305 | HCC70 PI103 0 1 72 |
| HCC70 | Sirolimus | 1 | 72 | 0.0032 | 2550.0 | 3414.3 | 1279.8 | -2.49 | 0.627 | 0.747 | 1.416 | HCC70 Rapamycin 0 1 72 |
| HCC38 | MK2206 | 1 | 72 | 0.0032 | 4362.5 | 4477.3 | 1295.5 | -2.49 | 0.971 | 0.974 | 1.789 | HCC38 MK2206 0 1 72 |
| BT-20 | AZD8055 | 2 | 72 | 0.0032 | 2842.0 | 3421.5 | 1018.6 | -2.49 | 0.799 | 0.831 | 1.748 | BT20 AZD8055 0 2 |
| HCC70 | KIN001-244 | 1 | 72 | 0.0032 | 3343.5 | 3263.0 | 1279.8 | -2.49 | 1.040 | 1.020 | 1.350 | HCC70 KIN001-244 0 1 72 |
| HCC70 | MK2206 | 1 | 72 | 0.0032 | 3306.0 | 3483.3 | 1279.8 | -2.49 | 0.929 | 0.949 | 1.444 | HCC70 MK2206 0 1 72 |